Table 1.

HAQ-DI and morning stiffness outcomes at week 52^a

Outcome	Placebo	Sirukumab 50mg q4w	Sirukumab 100mg q4w

	(n=556)	(n=557)	(n=557)

HAQ-DI, mean (SD) change from BL	−0.23 (0.57)	−0.45 (0.61)^b	−0.47 (0.60)^b
Clinically meaningful improvement from BL in HAQ-DI, n (%)^c	263 (47.1)	353 (63.4)^b	359 (64.5)^b
HAQ-DI ≤0.5, n (%)	69 (12.4)	153 (27.5)^b	163 (29.3)^b
Duration of daily morning stiffness (min), mean (SD) change from BL^d	−67.3 (196.98)	−99.1 (233.82)^e	−97.7 (231.53)^e

^an values are based on initial treatment assignment. ^bP<0.001 vs placebo. ^cMinimum clinically meaningful improvement, change of −0.22 from BL. ^dPlacebo, n=552; sirukumab 50 mg q4w, n=552; sirukumab 100 mg q2w, n=555. ^eP≤0.022 vs placebo.